Why Sanofi’s $2.2bn Dynavax deal is a high-stakes bet on adult vaccines

Sanofi to acquire Dynavax for $2.2B to boost adult vaccines. Find out how HEPLISAV-B and Z-1018 fit into Sanofi’s global immunization strategy.

Sanofi to acquire Dynavax for $2.2B to boost adult vaccines. Find out how HEPLISAV-B and Z-1018 fit into Sanofi’s global immunization strategy.